TY - JOUR
T1 - Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations
AU - Coeliac Dis Immunochip Consortium
AU - Rheumatoid Arthrit Consortium Int
AU - Int Scleroderma Grp
AU - Type 1 Diabet Genetics Consortium
AU - Marquez, Ana
AU - Kerick, Martin
AU - Zhernakova, Alexandra
AU - Gutierrez-Achury, Javier
AU - Chen, Wei-Min
AU - Onengut-Gumuscu, Suna
AU - Gonzalez-Alvaro, Isidoro
AU - Rodriguez-Rodriguez, Luis
AU - Rios-Fernandez, Raquel
AU - Gonzalez-Gay, Miguel A.
AU - Mayes, Maureen D.
AU - Raychaudhuri, Soumya
AU - Rich, Stephen S.
AU - Wijmenga, Cisca
AU - Martin, Javier
PY - 2018/12/20
Y1 - 2018/12/20
N2 - BackgroundIn recent years, research has consistently proven the occurrence of genetic overlap across autoimmune diseases, which supports the existence of common pathogenic mechanisms in autoimmunity. The objective of this study was to further investigate this shared genetic component.MethodsFor this purpose, we performed a cross-disease meta-analysis of Immunochip data from 37,159 patients diagnosed with a seropositive autoimmune disease (11,489 celiac disease (CeD), 15,523 rheumatoid arthritis (RA), 3477 systemic sclerosis (SSc), and 6670 type 1 diabetes (T1D)) and 22,308 healthy controls of European origin using the R package ASSET.ResultsWe identified 38 risk variants shared by at least two of the conditions analyzed, five of which represent new pleiotropic loci in autoimmunity. We also identified six novel genome-wide associations for the diseases studied. Cell-specific functional annotations and biological pathway enrichment analyses suggested that pleiotropic variants may act by deregulating gene expression in different subsets of T cells, especially Th17 and regulatory T cells. Finally, drug repositioning analysis evidenced several drugs that could represent promising candidates for CeD, RA, SSc, and T1D treatment.ConclusionsIn this study, we have been able to advance in the knowledge of the genetic overlap existing in autoimmunity, thus shedding light on common molecular mechanisms of disease and suggesting novel drug targets that could be explored for the treatment of the autoimmune diseases studied.
AB - BackgroundIn recent years, research has consistently proven the occurrence of genetic overlap across autoimmune diseases, which supports the existence of common pathogenic mechanisms in autoimmunity. The objective of this study was to further investigate this shared genetic component.MethodsFor this purpose, we performed a cross-disease meta-analysis of Immunochip data from 37,159 patients diagnosed with a seropositive autoimmune disease (11,489 celiac disease (CeD), 15,523 rheumatoid arthritis (RA), 3477 systemic sclerosis (SSc), and 6670 type 1 diabetes (T1D)) and 22,308 healthy controls of European origin using the R package ASSET.ResultsWe identified 38 risk variants shared by at least two of the conditions analyzed, five of which represent new pleiotropic loci in autoimmunity. We also identified six novel genome-wide associations for the diseases studied. Cell-specific functional annotations and biological pathway enrichment analyses suggested that pleiotropic variants may act by deregulating gene expression in different subsets of T cells, especially Th17 and regulatory T cells. Finally, drug repositioning analysis evidenced several drugs that could represent promising candidates for CeD, RA, SSc, and T1D treatment.ConclusionsIn this study, we have been able to advance in the knowledge of the genetic overlap existing in autoimmunity, thus shedding light on common molecular mechanisms of disease and suggesting novel drug targets that could be explored for the treatment of the autoimmune diseases studied.
KW - Celiac disease
KW - Rheumatoid arthritis
KW - Systemic sclerosis
KW - Type 1 diabetes
KW - Cross-disease meta-analysis
KW - Immunochip
KW - Autoimmune disease
KW - functional enrichment analysis
KW - GENOME-WIDE ASSOCIATION
KW - SUSCEPTIBILITY LOCI
KW - CELIAC-DISEASE
KW - VARIANTS
KW - IMPACT
KW - RISK
U2 - 10.1186/s13073-018-0604-8
DO - 10.1186/s13073-018-0604-8
M3 - Article
C2 - 30572963
VL - 10
JO - Genome medicine
JF - Genome medicine
SN - 1756-994X
IS - 1
M1 - 97
ER -